Klinički značajne interakcije imunosupresiva

Stručni rad - Stručni rad

• Autor: Vesna Bačić Vrca
• Autor: Iva Bužančić
• Autorova ustanova: Sveučilište u Zagrebu; Farmaceutsko-biokemijski fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Farmacija; Farmacija

Sažetak (engleski)

lmmunosuppressants are a relatively new group of medications with various chemical
entities and indications for use ranging from prevention of transplanted organs to
autoimmune and rheumatoid diseases. lt is beyond dispute that their use and indication
spectrum will grow with time. Immunosuppressants currently registered in Croatia
have 290 clinically significant drug interactions, 34.8 % of ali interactions are of the
level of clinical significance D, 32.8 % level X and 32.4 % level C. Cyclosporine is the
immunosuppressant with the largest number of drug interactions, while inhibitors of
TNF-a, inhibitors of interleukin and antithymocyte globulin have the fewest interactions.
lt is understandable that cyclosporine has most interactions since it has been in use and
in the world market for the longest time and has the widest indications. Even though
they have the fewest interactions, most interactions of TNF-a inhibitors are of level X
compared to level C and D interactions. Regarding the ATC classification system, immunosuppressants
mostly interact with drugs of groups J and L. These data are very important
in clinical practice, especially during combined drug therapy. Almost 20 % of ali
interactions are among immunosuppressants themselves. Based on their metabolism
mechanism via CYP3A4 and P-glycoprotein, one would conclude that the mechanism of
immunosuppressant interaction would mostly be of pharmacokinetic nature, but results
show that more than 50% of interactions are of a still unknown mechanism. This can be
attributed to the fact that immunosuppressants are quite new in the global drug market
and their use with other medications is still insufficiently investigated.

• Ključne riječi (hrvatski): imunosupresivi; interakcije imunosupresiva; ciklosporin; takrolimus
• Jezik: hrvatski
• Vrsta publikacije: Stručni rad - Stručni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran - domaća recenzija
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Farmaceutski glasnik
• Brojčani podaci: vol. 67, br. 11, str. 537-552
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:237082
• Datum objave publikacije: 2011-11
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2020-09-28 15:08:09